Avanir Pharmaceuticals (Nasdaq: AVNR) is focused on developing, acquiring and commercializing novel therapeutic products for the treatment of chronic diseases. Avanir's products and product candidates address therapeutic markets that include central nervous system disorders, cardiovascular disorders, inflammation and infectious disease. Avanir currently markets FazaCloÂ®, the only orally-disintegrating formulation of clozapine for the management of severely ill schizophrenic patients who fail to respond adequately to standard schizophrenic drug treatments. FazaClo is also indicated for reducing the risk of suicidal behavior in patients with schizophrenic or schizoaffective
Please check AVANIR Pharmaceuticals for more information.